Aadi bioscience appoints dave lennon, ph.d. as president and chief executive officer

Dr. lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mtor inhibitors leadership transition expected to accelerate growth and leverage ground-breaking nanoparticle technology in fyarro® to build a leading precision oncology company on track for interim analysis on 40 patients in tumor agnostic precision1 trial in patients with tsc1/tsc2 alterations and trial initiations in endometrial and neuroendocrine cancers before the end of  2023 los angeles , oct. 2, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies with mtor pathway alterations, today announced the appointment of dave lennon, ph.d. as president and chief executive officer.
AADI Ratings Summary
AADI Quant Ranking